1/31/12: progressive disease now with acquired EGFR T790M mutation,

treated with afatinib followed by afatinib+cetuximab

1/31/15: stable disease with acquired EGFR T790M mutation, continued on afatinib+cetuximab

10/15/15: progressive disease with maintained EGFR T790M mutation, treated with osimertinib

6/13/16: progressive disease with loss of EGFR T790M but maintained L858R mutation, treated with erlotinib

8/5/16: progressive disease, enrolled in hospice